Faeth Therapeutics Company Report

Company Overview

Name

Faeth Therapeutics Inc.

Mission of the Company

Faeth Therapeutics is pioneering a powerful new treatment paradigm in cancer care by combining metabolic optimization with anti-cancer drugs to unlock new ways of treating the disease.

Founded

No information is available regarding the exact date of founding or the specific founder(s).

Key People in the Company

• Anand Parikh, JD - CEO & Co-Founder: Previously CFO at Virta Health.

• Oliver Maddocks, PhD - Chief Scientific Officer & Co-Founder: Previously Professor of Cancer Biology & Metabolism, University of Glasgow.

• Debbie Chirnomas, MD, MPH - Chief Medical Officer: Leader in clinical development, previously at Arvinas, Gamida Cell, Pfizer.

• Tina Niazi - Head of Clinical Operations: Previously Executive Director of Clinical Operations at Iovance Biotherapeutics.

• Ryan Whitney - Head of Food Operations: Previously Strategic Finance Lead at Virta Health.

• Chandrasekhar Mothali - Head of Engineering: Previously Engineering Manager at Flatiron Health.

• Bridie Gahan - Head of Strategy & Finance: Previously venture capital investor at LifeForce Capital.

• Alan Sun - Head of Product: Previously Head of Product at Curebase.

Headquarters

No information is available regarding the specific headquarters location.

Number of Employees

No information is available regarding the number of employees.

Revenue

No information is available regarding the company's revenue.

What the Company is Known For

Faeth Therapeutics is known for leveraging metabolic data to create safer and more impactful cancer therapies through its MetabOS discovery platform.

Products

Overview

Faeth Therapeutics offers unique cancer treatment solutions that integrate metabolism and drug therapies.

Key Products

1. FTH-001/003 (Serabelisib + Sapanisertib)

• Mechanism of Action: “PIKTOR,” a PI3Kɑ inhibitor & dual mTORC1/2 inhibitor.

• Indication: Targets advanced endometrial cancer and other undisclosed solid tumors.

• Development Stage: Complete in Preclinical and Phase 1, progressing through Phase 2 and Phase 3.

2. FTH-002

• Mechanism: Precise non-essential amino acid restriction.

• Indications: Targets pancreatic cancer and rectal cancer.

• Development Stage: In progress through Preclinical, Phase 1, Phase 2, and Phase 3 for undisclosed solid tumors and non-oncology indications.

Recent Developments

Recent Developments

• Faeth Therapeutics is conducting multiple ongoing clinical trials, with a focus on metabolic data to enhance drug-nutrient interactions in cancer treatment.

New Products Launched

• The company has not explicitly listed any newly launched products apart from those in the development phases mentioned above.

New Features Added to Existing Products

• No information is available regarding additional new features for existing products.

Partnerships

• Faeth has achieved significant backing from leading investors and is involved in various clinical trials across multiple centers nationwide.

Additional Notes

• Faeth emphasizes the importance of precision nutrition in cancer treatment, aiming to make nutrition the fourth pillar of cancer care alongside surgery, radiotherapy, small molecule treatments, and biologics.

• The company's discovery platform, MetabOS, utilizes machine learning to identify metabolic interventions tailored to specific tumor types and patient genotypes.

• Faeth is committed to transforming cancer treatment by supplementing traditional therapies with nutritionally optimized interventions, aiming for improved efficacy and reduced toxicity in cancer therapies.

Pipeline and Research Highlights

• Faeth’s research includes leveraging genomic and metabolic insights to create personalized dietary interventions that could potentially enhance standard cancer treatments.

• The company’s trials and insights aim to starve tumors via precise nutrient control, coupled with traditional drugs for better cancer control and patient outcomes.

Public and Scientific Engagement

• Faeth has engaged with the public through various media channels highlighting their innovative approach to cancer treatment and their ongoing clinical trials exploring the nexus of diet and cancer therapy.